1. Home
  2. ACRV vs AERT Comparison

ACRV vs AERT Comparison

Compare ACRV & AERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • AERT
  • Stock Information
  • Founded
  • ACRV 2018
  • AERT 2012
  • Country
  • ACRV United States
  • AERT Singapore
  • Employees
  • ACRV N/A
  • AERT N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • AERT Professional Services
  • Sector
  • ACRV Health Care
  • AERT Consumer Discretionary
  • Exchange
  • ACRV Nasdaq
  • AERT Nasdaq
  • Market Cap
  • ACRV 40.4M
  • AERT 43.9M
  • IPO Year
  • ACRV 2022
  • AERT N/A
  • Fundamental
  • Price
  • ACRV $1.26
  • AERT $0.85
  • Analyst Decision
  • ACRV Buy
  • AERT
  • Analyst Count
  • ACRV 7
  • AERT 0
  • Target Price
  • ACRV $17.60
  • AERT N/A
  • AVG Volume (30 Days)
  • ACRV 287.7K
  • AERT 52.6K
  • Earning Date
  • ACRV 08-12-2025
  • AERT 08-14-2025
  • Dividend Yield
  • ACRV N/A
  • AERT N/A
  • EPS Growth
  • ACRV N/A
  • AERT N/A
  • EPS
  • ACRV N/A
  • AERT N/A
  • Revenue
  • ACRV N/A
  • AERT $70,198,000.00
  • Revenue This Year
  • ACRV N/A
  • AERT N/A
  • Revenue Next Year
  • ACRV $1,037.93
  • AERT N/A
  • P/E Ratio
  • ACRV N/A
  • AERT N/A
  • Revenue Growth
  • ACRV N/A
  • AERT N/A
  • 52 Week Low
  • ACRV $1.05
  • AERT $0.46
  • 52 Week High
  • ACRV $10.16
  • AERT $2.93
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 43.05
  • AERT 36.64
  • Support Level
  • ACRV $1.34
  • AERT $0.80
  • Resistance Level
  • ACRV $1.48
  • AERT $1.04
  • Average True Range (ATR)
  • ACRV 0.10
  • AERT 0.06
  • MACD
  • ACRV -0.01
  • AERT -0.03
  • Stochastic Oscillator
  • ACRV 17.24
  • AERT 16.67

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

Share on Social Networks: